Does Cosentyx (secukinumab) reduce the effectiveness of vaccines?
Cosentyx is an immune-modulating biologic that targets interleukin-17A (IL-17A). Because it changes immune signaling, people often worry it could weaken how well vaccines work. The key practical point is that vaccine response depends on two things: what vaccine is used (inactivated vs live) and what immune readout (antibody levels or protection) is being measured.
Your question is specifically about “vaccine-induced immunity,” but you haven’t provided any study results or prescribing information text to cite about Cosentyx and vaccine responses. If you share the label language or a study excerpt you’re looking at, I can interpret it directly.
Which vaccines matter most: live vaccines vs non-live vaccines?
For most immunomodulating therapies like IL-17 blockers, guidance typically distinguishes between:
- Live vaccines (generally avoided during treatment because they can carry a risk of infection in immunosuppressed patients)
- Inactivated vaccines (generally allowed, with the expectation they still produce an immune response, though that response can be lower than in people not on the drug)
To answer your question accurately for Cosentyx, we need the specific vaccine guidance and the specific clinical data being referenced.
What does “vaccine-induced immunity” mean in studies?
Researchers may measure different outcomes, such as:
- Antibody titers after vaccination
- Durability of the antibody response
- Cell-mediated immune responses
- Real-world protection (e.g., fewer infections)
Different studies can reach different conclusions depending on which endpoint they use. Without the study details, it’s not possible to say whether Cosentyx “changes” immunity in a meaningful clinical way.
What do patients usually do in practice?
Clinically, patients and prescribers usually focus on:
- Completing recommended vaccinations before starting treatment when possible
- Using the correct vaccine type (and avoiding live vaccines when advised)
- Timing vaccines appropriately around dosing if the clinician recommends it
If you tell me which vaccine you mean (flu, COVID-19, shingles, pneumococcal, HPV, etc.) and whether it’s a live or inactivated formulation, I can narrow the answer.
Bottom line (what can be said without the missing source text)
Cosentyx works by altering IL-17A–mediated immune pathways, so it can plausibly affect vaccine responses. Whether it meaningfully reduces vaccine-induced immunity depends on vaccine type and the specific clinical evidence for that vaccine.
Quick questions so I can answer precisely
1) Which vaccine are you asking about (COVID-19, flu, shingles, etc.)?
2) Are you looking for the general guidance from the Cosentyx prescribing information, or a specific study result?
Sources
No sources were provided in the prompt.